ESC 365 - Exploring the effects of mavacamten through hemodynamic force analysis in patients with obstructive hypertrophic cardiomyopathy

ESC Premium Access

Exploring the effects of mavacamten through hemodynamic force analysis in patients with obstructive hypertrophic cardiomyopathy

Session: Cardiac myosin inhibitors for treatment of hypertrophic obstructive cardiomyopathy

Topic: Pharmacotherapy

Speaker: Doctor A. Milazzo (Florence, IT)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Doctor Alessandra Milazzo

Careggi University Hospital (AOUC), Florence (Italy)

1 presentation

0 follower

3 more presentations in this session

Serial changes in left and right ventricular global longitudinal strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from VALOR-HCM trial

Speaker: Doctor M. Desai (Cleveland, US)

A comprehensive evaluation of available evidence of mavacamten in obstructive HCM: a meta-analysis of randomised controlled trials.

Speaker: Doctor A. Elmorsy (Tanta, EG)

Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?

Speaker: Doctor M. Lima (Lisbon, PT)

Access the full session

Cardiac myosin inhibitors for treatment of hypertrophic obstructive cardiomyopathy

Speakers: Doctor A. Milazzo, Doctor M. Desai, Doctor A. Elmorsy, Doctor M. Lima

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources